Soligenix, Inc. (SNGX) stock
Close on Nov 16, 2026Market cap $6.27MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $6.27M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.94
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$10.24M
- EPS, diluted
- -$2.14
- Free cash flow
- -$10.27M
- Book value per share
- $0.42
- Diluted shares
- 16M
Trading
- Previous close
- $0.32
- Open
- $0.32
- Day's range
- $0.27 – $0.32
- Volume
- 694,929
- Average volume (20 days)
- 142,315
- 52-week range
- $0.27 – $1.70
- RSI (14 days)
- 27.5
- Volatility (1 year)
- 129.3%
- Relative volume
- 3.25×
Market cap history
Month-end market cap since 2011, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 16, 2026. The S&P 500 is measured by the SPY fund.
| Period | SNGX | S&P 500 | Difference | SNGX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -18.4% | -3.1% | −15.3 pts | ||
| 3 months | -27.9% | -4.5% | −23.5 pts | ||
| Year to date | -78.5% | +9.4% | −87.8 pts | ||
| 1 year | -79.0% | +11.3% | −90.3 pts | ||
| 3 years | -95.5% | +70.4% | −166.0 pts | -64.5% | +19.4% |
| 5 years | -99.9% | +68.6% | −168.5 pts | -73.4% | +11.0% |
| 10 years | -100.0% | +297.7% | −397.7 pts | -54.5% | +14.8% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Soligenix filed with the SEC as exhibits to Form 8-K or 6-K
- News
- News
- News
- News
- News
- News
About Soligenix
Pharmaceutical Preparations
Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing therapies for rare diseases with unmet medical needs. The company operates two primary business segments: Specialized BioTherapeutics and Public Health Solutions. Its biotherapeutics pipeline includes synthetic hypericin treatments, primarily HyBryte for cutaneous T-cell lymphoma and SGX302 for psoriasis, alongside dusquetide formulations for rare inflammatory conditions. Its public health segment concentrates on biodefense medical countermeasures, including ricin toxin and filovirus vaccine candidates that utilize a proprietary heat-stabilization platform. The company's end users encompass patients suffering from rare oncology and inflammatory disorders, as well as government agencies and public defense organizations that support and procure biodefense countermeasures.
Company profile, executives and historySoligenix stock: common questions
What is Soligenix's stock price?
SNGX closed at $0.29 on Nov 16, 2026, down 10.22% on the day. Over the past 52 weeks it traded between $0.27 and $1.70.
What is Soligenix's market cap?
Soligenix was worth $6.27M at the close on Nov 16, 2026: the share price times the diluted shares outstanding.
What is SNGX's P/E ratio?
Soligenix lost money over fiscal 2025 (diluted EPS -$2.14), so it has no meaningful P/E ratio.
Does Soligenix pay a dividend?
No. Soligenix has not paid a cash dividend over the last twelve months.
How has SNGX stock performed over the past year?
Including dividends, SNGX returned -79.0% over the past year, against +11.3% for the S&P 500.
How many SNGX shares are sold short?
0M shares were sold short at the latest FINRA report, 0.31% of the float, or 1.0 days of average trading volume.
Who are Soligenix's competitors?
Companies most similar to Soligenix by business, industry and size include HIND, LSTA, ATNM, SER, IXHL.
See a number that looks wrong?